Scopus BioPharma

General Information
Business:

 

We are a biotechnology company focused on developing novel therapeutics targeting the endocannabinoid system. This system is critical for maintaining overall human health by modulating key functions within the body, including those relating to the immune, metabolic and nervous systems. The endocannabinoid system is comprised of chemical compounds, or cannabinoids, that interact with cannabinoid receptors which are located throughout the body. Endogenously-produced cannabinoids are known as endocannabinoids. Cannabinoids can also be derived from the cannabis plant or can be synthetically produced. The most well-known and researched plant-derived and synthetically-produced cannabinoids are CBD and THC. We intend to pursue FDA approval, as well as other U.S. and non-U.S. regulatory approvals, for our proprietary drug candidates.

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 2
Founded: 2019
Contact Information
Address 420 Lexington Avenue, New York, NY 10170, US
Phone Number (212) 479-2513
Web Address http://www.scopusbiopharma.com
View Prospectus: Scopus BioPharma
Financial Information
Market Cap $85.9mil
Revenues $0 mil (last 12 months)
Net Income $-1.3 mil (last 12 months)
IPO Profile
Symbol SCPSA/SCPSW/SCPSC
Exchange NASDAQ
Shares (millions): 0.7
Price range $6.50 - $6.50
Est. $ Volume $4.6 mil
Manager / Joint Managers Benchmark Company
CO-Managers -
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change